Trade Caribou Biosciences, Inc. - CRBU CFD

About Caribou Biosciences Inc

Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer. It is focused on developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. It also offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics and industrial biotechnology. The Company's pipeline includes CB-010, CB-011, CB-012 and CB-020.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Caribou Biosciences Inc revenues totaled $7M. Net loss totaled to $48.4M.